A T-cell engager is a format - one arm grabs a T cell, the other grabs a tumor antigen - and the format itself is a crowded genus. US11492408B2, "Bi-specific T-cell engager specific for BCMA," issued November 8, 2022 to UCL Business Ltd, stakes a species inside it by fixing the tumor target.
The genus is the bispecific-engager architecture: a molecule that simultaneously binds CD3 on a T cell and an antigen on a cancer cell, redirecting the T cell to kill. Dozens of assignees - Amgen prominently among them - hold claims across that format. A claim to the format broadly would collide with that prior art.
The species limitation is the BCMA target. B-cell maturation antigen (BCMA) is a multiple-myeloma marker, and a claim drawn to a BCMA-specific engager narrows the genus to molecules that hit that antigen. The CPC tags confirm the construction: C07K 16/2878 (antibody to the relevant receptor family) and C07K 16/2809 (anti-CD3), the two arms of the engager.
The enforcement consequence is the usual genus-species trade. A CD19-specific or GPRC5D-specific engager - other myeloma or lymphoma targets - does not read on a BCMA-specific claim. The claim reaches only competitors building BCMA engagers, which both clears the format prior art and confines the patent to the BCMA commercial lane.
For the landscape, BCMA became one of the most contested antigens in oncology IP precisely because multiple modalities - CAR-T, antibody-drug conjugates, and bispecific engagers - all converged on it. A T-cell-engager species claim like this one is one tile in that larger BCMA mosaic, and freedom-to-operate for any BCMA program means mapping the species across all three modalities.